Changes in Beneficial Ownership · 4
Danaher Corporation
DHRNYSEEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1785877278.xml
Filing details
- Report period
- 2026-07-31
- Issuer
- DANAHER CORP /DE/
- Issuer CIK
- 0000313616
- Trading symbol
- DHR
Reporting owner 1
- Name
- FILLER LINDA
- Reporting owner CIK
- 0001292810
- Relationship
- Director
- Address
- 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON, DC, 20037
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phantom shares[F1] | 0[F2] | 2026-07-31 | A · Form 4 | 18.333 | A | 194.98 | [F3] | [F3] | Common Stock | 18.333 | 8,954.736 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Under the terms of the Non-Employee Directors Deferred Compensation Plan (the "Plan") established under the Danaher Corporation Omnibus Incentive Plan, the reporting person can defer all or part of the cash director fees they are entitled to receive each quarter. Amounts deferred under the plan (which includes dividend accruals on plan balances and may also include cash director fees) are converted into a particular number of notional shares of Danaher common stock, calculated based on the closing price of Danaher's common stock on the quarterly date such amounts otherwise would have been paid. The price shown in Table II, Column 8 above is the closing price per share of the Danaher common stock as reported on the NYSE on the transaction date noted above.↩ 1
- F2
- Upon distribution, the phantom shares convert into shares of Danaher common stock on a one-for-one basis.↩ 1
Signature 1
- Signed
- /s/ James F. O'Reilly, attorney-in-fact for Linda Filler
- Date
- 2026-08-04
Company context
Danaher is a leading global life sciences and diagnostics innovator, committed to advancing the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges - accelerating the moment scientific discovery becomes human impact. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. That’s innovation at the speed of life. Explore more at www.danaher.com.